Canton Hathaway LLC increased its position in Eli Lilly And Co (NYSE:LLY) by 1,566.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 500 shares of the company’s stock after purchasing an additional 470 shares during the period. Canton Hathaway LLC’s holdings in Eli Lilly And Co were worth $56,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of LLY. Enterprise Trust & Investment Co acquired a new position in Eli Lilly And Co in the 3rd quarter worth approximately $27,000. Prestige Wealth Management Group LLC purchased a new stake in Eli Lilly And Co in the 2nd quarter worth approximately $34,000. Meridian Wealth Management LLC purchased a new stake in Eli Lilly And Co in the 1st quarter worth approximately $38,000. Manchester Financial Inc. purchased a new stake in Eli Lilly And Co in the 2nd quarter worth approximately $40,000. Finally, Litman Gregory Asset Management LLC purchased a new stake in Eli Lilly And Co in the 2nd quarter worth approximately $47,000. 76.72% of the stock is owned by hedge funds and other institutional investors.
LLY has been the subject of a number of research analyst reports. Bank of America set a $120.00 target price on shares of Eli Lilly And Co and gave the stock a “neutral” rating in a research report on Tuesday, September 10th. ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Nine analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $122.92.
LLY stock opened at $108.36 on Friday. Eli Lilly And Co has a 12-month low of $104.17 and a 12-month high of $132.13. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 4.98. The company has a market cap of $104.61 billion, a price-to-earnings ratio of 19.52, a PEG ratio of 1.86 and a beta of 0.16. The company has a 50 day moving average of $111.50 and a two-hundred day moving average of $114.76.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.05. The business had revenue of $5.64 billion for the quarter, compared to the consensus estimate of $5.59 billion. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. Eli Lilly And Co’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the firm earned $1.48 EPS. On average, research analysts anticipate that Eli Lilly And Co will post 5.73 EPS for the current year.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
See Also: The Structure of a Futures Contract
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.